EZH2 and small cell carcinoma: EZH2, AURKA and DLL3 are promising targets for which clinically relevant inhibitors are in early phase trials against NEPC and small-cell carcinoma (NCT03480646; NCT04179864; NCT01799278; NCT04702737; NCT04471727).